CHD Bioscience Appoints Dr. Catherine Angell Sohn to its Board of Directors

CHD Bioscience Appoints Dr. Catherine Angell Sohn to its Board of Directors

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE CHD Bioscience, Inc.

Healthcare Executive Brings Expertise in New Product Commercialization, Licensing, and Mergers and Acquisitions

FORT COLLINS, Colo., Feb. 3, 2014 /PRNewswire/ -- CHD Bioscience, Inc. a development-stage biopharmaceutical company focused on the discovery, development and commercialization of novel products active against multi-resistant pathogens, is pleased to announce the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board of Directors.  Dr. Sohn will become CHD Bioscience's eighth board member.    

"We are very excited that Dr. Sohn has agreed to serve on our board. She has significant new product commercialization and business development expertise, relevant board experience and brings a strong healthcare perspective," said Ted Ziemann, Chairman of the Board at CHD Bioscience, Inc.  "As we move forward with commercialization of our first product, VERIOX™, in both the United States and internationally, Dr. Sohn's transaction experience and pharmaceutical and consumer healthcare network will add tremendous value and bring great insights to the company in future licensing deals."

"I am honored to join the CHD Board of Directors at this exciting time," stated Dr. Sohn. "CHD Bioscience's focus on treating and preventing infections due to multi-resistant pathogens addresses a key unmet need in the United States and internationally.  I look forward to working with the Board and Management to help achieve the company's business goals and to bringing new products to patients." 

Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliances at GlaxoSmithKline Consumer Healthcare (1998-2010), where she spearheaded a series of U.S. and global licensing, merger and acquisition transactions. During her 28-year tenure at GlaxoSmithKline, Dr. Sohn was Vice President for Worldwide Strategic Product Development for the Cardiovascular, Pulmonary and Metabolic therapeutic areas with responsibility for product strategy, valuation and strategic commercial leadership of assets from Phase 1 through global life cycle management (1994-1997).  She established the U.S. Vaccine Business Unit, leading the commercial launch of the company's first vaccine in the U.S. (1986-1990), which grew to more than $100 million in sales. She was the Product Marketing Director for the successful U.S. launch of the company's central nervous system product (1990-1993), which subsequently grew to more than $1 billion in sales.  Dr. Sohn began her pharmaceutical career at SmithKline & French in the Anti-infective Medical Affairs group in 1982.

Dr. Sohn is an independent director on the Boards of Jazz Pharmaceuticals (NASDAQ: JAZZ), Landec Corp. (NASDAQ: LNDC), Neuralstem, Inc. (NYSEMKT: CUR) and Dohmen Life Science Services (privately held), and an NACD Governance Fellow.  Dr. Sohn is also Dean's Professor (adjunct) at the University of the Sciences in Philadelphia and serves on the Board of the World Affairs Council of Philadelphia, the Dean's Advisory Council for Drexel University School of Public Health and the External Advisory Board for Drexel University Close School of Entrepreneurship. She is a member of the Ben Franklin Technology Partners Life Science Investment Committee and Springboard Enterprises' Life Science Council.

A native of California, Dr. Sohn received a Doctor of Pharmacy from the University of California, San Francisco and a Certificate of Professional Development from The Wharton School at the University of Pennsylvania, and is a Certified Licensing Professional.

About CHD Bioscience

CHD Bioscience is a development-stage biopharmaceutical company focused on creating novel patented products that successfully kill most deadly pathogens blamed for the rising number of healthcare-associated infections worldwide. CHD's mission is to become a leader in discovering, developing and bringing to market products that prevent and treat infectious disease in humans and animals in both industrialized and developing nations. The company is based in Fort Collins, Colorado.

Media Contact: Laura de Zutter, MCS Healthcare Public Relations, (800) 477-9626, laurad@mcspr.com   

©2012 PR Newswire. All Rights Reserved.